Initial results of a recent study revealed that there is a possibility to use a new drug to reduce migraine attacks in children and adolescents.
The study was conducted by researchers from Ann Hospital and Robert H Laurie for Children in Chicago and Fennberg College of Medicine at Northwestern University in the United States, and its results will be shown at the 77th annual meeting of the American Academy of Neuroscience to be held next April in San Diego and online, and the Yoric Alert website was written about it.
The study revealed that the Zonisamide used to treat nervous cramps may help reduce the number of headaches in children and adolescents with migraine. Although the study does not prove categorically the effectiveness of the drug in reducing the number of headache days, it indicates that there is a link between its use and the low rate of migraine attacks.
What is the sister?
The sister is defined as an acute headache that may last or days, and it affects women more than men, and it is believed that factors such as heredity and electrical activity in the brain and the neurotransmitter serotonin play a role in it.
The migraine is also known as “migraines”, and headaches usually begin in the forehead, on the side of the head, or around the eyes, and it is sharp or pulsating “beating like palpitations”, and the headache usually gets worse gradually, as it may also worse the slightest movement, bright light or high sound, as the person may feel nausea and may vomit.
In some cases, a headache seizure may precede a stage known as AURA, a group of temporary neurological symptoms that may include visual disorders such as vision of flashing or blind spots, numbness or tingling in the face or limbs, and sometimes it is difficult to speak.
Mute treatments depend on relieving symptoms and reducing the number of seizures, and include analgesic drugs to treat Nubia during their occurrence, and preventive treatments that help reduce their repetition, such as some epilepsy medications, antidepressants, blood pressure medications, and botox injection. In addition, lifestyle changes can contribute to better control over the migraine, such as improving sleep quality, avoiding stimuli, and reducing stress.
“The sister is a prejudiced disease for children and adolescents, as it may lead to absenteeism from school and influence daily activities. Currently, there is only one drug accredited by the American Food and Drug Administration to prevent the sister in this age group,” said Dr. Anisa Kelly, the main author of this study and professor at the Faculty of Medicine at Northwestern University in Chicago. “The results of our study are encouraging, as it shows that Zonisamide may be an additional option to help reduce migraine attacks,” she added.
The researchers reviewed the health records of 256 children and adolescents who were diagnosed with migraine and were prescribed to them as a preventive treatment. Among them, 28% (approximately 72 participants) suffered from a sister -resistant sister, that is, they did not respond effectively to two or more drugs of previous drugs.
The researchers documented the number of headache days per month for each participant before starting and after eating the Xunismide. Then they divided the participants into 3 sub -groups based on the period when they took the medicine before visiting the follow -up with the doctor. The first group continued in the first month, the second group in 2-6 months, and the third group after 6 months.
The study indicated that the drug was more effective after at least two months of use, and it was noted that the drug was effective for patients who suffer from the sister -in -law that resist treatment or who had less severe forms of disease.
Despite the promising results, Dr. Kelly indicated that there were some restrictions in the study, as patients who took the drug with another group did not consume it, which requires the need for future studies with control groups to confirm these results.